Medications That Worsen Sleep: The Pharmacological Evidence by Drug Class

Most patients who develop insomnia after starting a new medication assume the connection is coincidental, or that poor sleep is simply part of being ill. Most clinicians, pressed for time, attribute the symptom to the underlying condition rather than the treatment. The result is a systematic blind spot: medication-induced sleep disruption is common, mechanistically well-understood, and frequently missed at the prescribing encounter.

The pharmacological evidence on which drug classes disrupt sleep, through which mechanisms, and with what severity is not obscure — it is documented in the prescribing literature and in decades of polysomnographic research. Understanding it changes how patients communicate with their physicians, what questions they ask, and whether a treatable cause of worsening sleep goes unaddressed for months or years. For context on how untreated sleep disruption compounds over time when an underlying pharmacological trigger goes unidentified, the clinical trajectory is documented in full.

The Mechanisms: How Medications Disrupt Sleep Architecture

Medications disrupt sleep through several distinct pharmacological mechanisms, and knowing which mechanism applies to a specific drug predicts which aspect of sleep it will affect.

CNS stimulation and sympathomimetic activation increase arousal by raising norepinephrine, dopamine, or cortisol levels, raising the arousal threshold so that sleep onset is delayed and maintenance is impaired. Stimulant medications, decongestants, corticosteroids, and some antidepressants work through this pathway.

REM sleep suppression is produced by multiple drug classes including SSRIs, SNRIs, TCAs, monoamine oxidase inhibitors, and beta-blockers. REM sleep normally constitutes 20 to 25 percent of total sleep time in healthy adults; pharmacological REM suppression produces compensatory REM rebound on withdrawal, with vivid or disturbing dreams, and long-term REM deprivation contributes to mood dysregulation, memory impairment, and hyperarousal during waking.

Melatonin suppression is produced by beta-blockers, which block the beta-1 adrenergic receptors in the pineal gland that drive nocturnal melatonin synthesis. Lipophilic beta-blockers — propranolol, metoprolol — cross the blood-brain barrier and suppress melatonin substantially; hydrophilic agents — atenolol — produce less melatonin suppression and fewer sleep complaints at equivalent antihypertensive doses.

Dopamine pathway disruption is the mechanism by which dopamine antagonists — antipsychotics, some antiemetics — worsen or induce restless legs syndrome. The dopaminergic pathways that modulate sensorimotor function in the spinal cord and basal ganglia are disrupted, producing the characteristic sensory-motor urgency of RLS or worsening existing symptoms to a clinically severe degree.

Upper airway muscle relaxation is the mechanism by which opioids, benzodiazepines, and other GABA-potentiating agents worsen obstructive sleep apnea. These drugs reduce the tone of the genioglossus and other upper airway dilator muscles, lowering the anatomical threshold at which the airway collapses during sleep, and simultaneously blunt the hypercapnic and hypoxic arousal responses that normally terminate apnea events.

Adenosine pathway antagonism is produced by theophylline, used in some asthma regimens. Adenosine is the primary sleep-promoting molecule; its accumulation during wakefulness drives sleep pressure. Theophylline blocks adenosine receptors, reducing sleep pressure and increasing arousal — the same mechanism as caffeine, but at higher receptor affinity.

Antidepressants: The Most Clinically Complex Category

Antidepressants represent the most pharmacologically heterogeneous drug class in terms of sleep effects, because different agents target different receptor systems with different downstream consequences.

SSRIs (fluoxetine, sertraline, escitalopram, paroxetine) and SNRIs (venlafaxine, duloxetine) are among the most commonly prescribed medications in the United States, and sleep disruption is among their most frequent side effects. The primary mechanisms are REM suppression — SSRIs reduce REM density and total REM time by 30 to 50 percent at therapeutic doses — and serotonergic activation of arousal pathways, which increases sleep latency and produces nighttime wakings. Fluoxetine has the longest half-life and most pronounced activating effect; paroxetine has additional antihistamine and anticholinergic properties that produce sedation but also morning cognitive impairment. Sertraline and escitalopram have intermediate profiles.

Medication-induced bruxism — rhythmic jaw clenching and tooth grinding during sleep — is specifically associated with SSRIs and SNRIs, affecting an estimated 3 percent of users. It represents a distinct serotonin-mediated motor dysregulation during sleep that is underreported because patients are typically unaware it is occurring.

TCAs (amitriptyline, nortriptyline, doxepin) are more sedating — through antihistamine blockade — but also suppress REM substantially and produce anticholinergic effects including rapid heart rate, dry mouth, and urinary retention that can disrupt sleep indirectly. Low-dose doxepin (3-6 mg) has FDA approval for insomnia and works primarily through histamine H1 blockade rather than serotonin reuptake inhibition at these doses.

Mirtazapine is sedating through antihistamine and alpha-2 blockade and generally improves sleep continuity in the short term, though weight gain and next-day sedation are limiting factors. Bupropion has a norepinephrine and dopamine mechanism with minimal serotonin activity, producing an activating profile that causes insomnia at full doses — timing the dose in the morning rather than evening significantly mitigates this effect.

Medications That Specifically Worsen OSA

Obstructive sleep apnea is the sleep disorder most directly exacerbated by pharmacological agents, because multiple drug classes impair the upper airway neuromuscular tone that prevents airway collapse.

Opioids are the most clinically significant OSA-worsening drug class. They reduce upper airway muscle tone through mu-opioid receptor activity in the brainstem, increase central sleep apnea events by blunting the hypercapnic arousal response, and produce an irregular breathing pattern (Biot’s respiration at high doses) that is distinct from the regular obstructive pattern of untreated OSA. Patients with existing OSA who require opioid analgesia — postoperatively, for cancer pain, or for chronic pain management — should have their CPAP titration reconsidered, as opioid-induced changes to breathing pattern may alter the optimal pressure needed.

Benzodiazepines (diazepam, clonazepam, temazepam) and Z-drugs (zolpidem, eszopiclone) both potentiate GABA-A receptors and reduce upper airway muscle tone. In patients with mild undiagnosed OSA, these agents can precipitate clinically significant desaturation events. In patients with diagnosed OSA who are not adherent to CPAP, prescribing benzodiazepines or Z-drugs for comorbid insomnia creates a compounding risk profile that should be explicitly discussed at the prescribing encounter.

Muscle relaxants including baclofen (GABA-B agonist) similarly relax pharyngeal and genioglossus musculature. Alcohol, though not a prescribed medication, operates through GABA pathways and produces the same effect, substantially increasing AHI in individuals with existing OSA and triggering clinically meaningful desaturation in individuals who would otherwise be subclinical.

Medications That Specifically Worsen or Induce RLS

Restless legs syndrome has a documented pharmacological trigger category that is frequently overlooked at prescribing: dopamine antagonists. This class includes all antipsychotics (typical and atypical, though the effect is strongest with dopamine D2-blocking agents), the antiemetic metoclopramide, the antihistamine promethazine, and the antinausea agent prochlorperazine. Any patient with a known RLS diagnosis — or a family history consistent with RLS — who requires one of these agents should have their prescribing physician informed of the RLS risk.

SSRIs and SNRIs worsen RLS in a subset of patients, through mechanisms that may involve serotonin-mediated inhibition of dopamine pathways in the spinal cord. The clinical effect is variable — some patients with pre-existing RLS experience significant worsening on starting an SSRI, while others do not — making prospective monitoring more reliable than prediction. Mirtazapine also appears to worsen RLS in some patients despite its general sleep-promoting profile.

First-generation antihistamines (diphenhydramine, hydroxyzine) commonly worsen RLS. This is relevant because diphenhydramine is the active ingredient in most over-the-counter sleep aids (Benadryl, ZzzQuil, Unisom SleepTabs). For a patient with undiagnosed or mild RLS reaching for an OTC sleep aid, diphenhydramine use is likely to worsen rather than improve their ability to fall asleep.

Corticosteroids, Decongestants, and Thyroid Medications

Corticosteroids (prednisone, methylprednisolone, dexamethasone) produce insomnia through HPA axis activation — the same pathway by which chronic psychological stress impairs sleep. Evening corticosteroid dosing is more disruptive than morning dosing for this reason; shifting to a morning dose when clinically feasible reduces insomnia risk without altering anti-inflammatory efficacy. Long-term corticosteroid use also reduces slow-wave sleep, impairing growth hormone secretion and physical recovery during sleep.

Decongestants containing pseudoephedrine and phenylephrine act as alpha-1 adrenergic agonists. They produce dose-dependent sympathomimetic arousal and insomnia. The effect is common, frequently underappreciated because patients attribute disturbed sleep to the illness requiring the decongestant, and resolvable by switching to nasal saline rinses or intranasal corticosteroids for congestion management when sleep is a priority.

Levothyroxine at doses producing a biochemically hyperthyroid state — suppressed TSH — causes insomnia, palpitations, and heat intolerance that directly disrupts sleep. Patients on thyroid hormone replacement who develop insomnia warrant TSH monitoring before assuming a primary sleep disorder.

Statins, particularly simvastatin and atorvastatin, are associated with a minority of patients developing myalgia or myopathy — statin-related muscle discomfort that worsens at night and disrupts sleep through pain-mediated arousal rather than through central nervous system effects. Switching from a lipophilic statin (simvastatin) to a hydrophilic agent (pravastatin, rosuvastatin) may resolve this for affected patients.

Clinical Management: What Patients Can Do

The first step when a patient suspects medication-related sleep disruption is a structured medication review — listing all prescription medications, over-the-counter agents, and supplements, and noting when each was started relative to when sleep changed. Temporal correlation between a new medication and sleep onset is the strongest initial indicator that a pharmacological cause is present.

Timing adjustments are often the lowest-risk first intervention. Moving a corticosteroid dose from evening to morning, taking a stimulant as early as possible in the day, or switching a beta-blocker from a lipophilic to hydrophilic formulation are clinically validated steps that can be discussed with a prescribing physician without changing the therapeutic agent.

Dose adjustment — reducing to the lowest effective dose for the treating condition — is appropriate for many medication classes where sleep disruption is dose-dependent. This requires a risk-benefit discussion specific to the condition being treated.

For patients whose prescribing physicians are not aware of the sleep-medication interaction, bringing a documented sleep diary — noting sleep onset time, number of wakings, estimated total sleep, and daytime function — alongside the medication list provides the kind of structured clinical information that facilitates a productive conversation.

Understanding the biological predispositions that make some patients more sensitive to medication-induced sleep disruption — including genetic variants in RLS susceptibility and the hyperarousal trait underlying insomnia heritability — provides additional context for why the same medication affects different patients differently.

About the Author

This article was reviewed by Dr. Dmitriy Kolesnik, MD, board-certified in Sleep Medicine, Psychiatry, and Neurology, and Medical Director of Vector Sleep Diagnostic Center since 2009. Dr. Kolesnik completed his medical training at St. Petersburg State Medical University and holds a Clinical Instructor appointment in the Department of Neurology at Weill Cornell Medicine since 2012. Patients experiencing sleep disruption that may be medication-related can request a sleep evaluation at Vector Sleep Diagnostic Center to request a consultation.

Frequently Asked Questions

Which medications most commonly cause insomnia?
SSRIs and SNRIs are the most frequently prescribed insomnia-causing medications, disrupting sleep through REM suppression and serotonergic arousal pathway activation. Stimulants (amphetamines, methylphenidate), corticosteroids, and decongestants containing pseudoephedrine also commonly cause insomnia through sympathomimetic mechanisms. Beta-blockers suppress melatonin secretion, particularly lipophilic agents like propranolol and metoprolol. Timing adjustments — taking activating medications as early in the day as possible — can often reduce insomnia without changing the agent.

Can sleep medications like Ambien actually make sleep worse?
In certain contexts, yes. Z-drugs (zolpidem, eszopiclone) and benzodiazepines reduce upper airway muscle tone, which worsens obstructive sleep apnea in individuals who have it — diagnosed or not. They also suppress slow-wave sleep at higher doses, reducing restorative sleep quality despite increasing total sleep time. On discontinuation after regular use, rebound insomnia — sleep that is worse than before the medication was started — is common, which can trap patients in a cycle of escalating dependence. These agents are appropriate for short-term use but not as long-term insomnia management.

Do antidepressants affect REM sleep?
Yes, significantly. SSRIs, SNRIs, TCAs, and MAOIs all suppress REM sleep, reducing REM duration by 30 to 50 percent in many patients at therapeutic doses. REM is the sleep stage associated with emotional memory processing and mood regulation. Long-term REM suppression can contribute to emotional blunting and vivid dreams or nightmares on dose reduction or discontinuation (REM rebound). Mirtazapine and low-dose trazodone are notable exceptions that generally preserve or enhance slow-wave sleep without substantial REM suppression.

What over-the-counter medications worsen restless legs syndrome?
Diphenhydramine — the active ingredient in most OTC sleep aids (Benadryl, ZzzQuil, Unisom SleepTabs) — worsens RLS by blocking the H1 receptor in ways that ultimately inhibit dopamine signaling. This makes OTC sleep aids contraindicated for patients with RLS. Nausea medications sold over the counter (dimenhydrinate, meclizine) may also worsen RLS. Iron deficiency is the most important treatable RLS modifier: serum ferritin below 75 ng/mL correlates with symptom severity, and iron supplementation to normalize ferritin reduces RLS symptoms independent of other interventions.

Can beta-blockers cause sleep problems?
Yes, particularly lipophilic beta-blockers that cross the blood-brain barrier. Propranolol and metoprolol suppress nocturnal melatonin secretion by blocking beta-1 adrenergic receptors in the pineal gland — the same pathway responsible for the circadian rise in melatonin that promotes sleep onset. They also suppress REM sleep and have been associated with nightmares. Hydrophilic beta-blockers such as atenolol have less CNS penetration and produce fewer sleep complaints at equivalent antihypertensive doses. Patients experiencing insomnia or nightmares on a lipophilic beta-blocker may benefit from a switch to atenolol, which can be discussed with their prescribing physician.

If you are experiencing sleep disruption that may be medication-related — or have an established sleep disorder that seems to be worsening on a new prescription — a comprehensive evaluation can help distinguish pharmacological from primary sleep disorder causes. Contact Vector Sleep Diagnostic Center at (718) 830-2800 or request an appointment online to speak with Dr. Kolesnik’s team.